Abstract
BackgroundPancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis that lacks specific diagnostic markers. Mucin 5AC (MUC5AC) is a member of the mucin family, a heterogeneous group of high molecular weight, heavily glycosylated proteins that could be either membrane-bound or secreted. This multi-central study is to evaluate the performance of serum MUC5AC in combination with carbohydrate antigen 19-9 (CA19-9) for the diagnosis of PC in Asian.MethodsSixty-one patients with PC (comprised of early pancreatic cancer [n = 30] and late pancreatic cancer [n = 31] patients), 29 benign control, 35 choledocholithiasis, 25 chronic pancreatitis, and 34 healthy controls, were recruited from two hospitals. Serum levels of MUC5AC were evaluated by commercial ELISA kits. CA19-9 was measured by chemiluminescence immunoassay. The cutoff value of MUC5AC was determined based on optimal sensitivity and specificity.ResultsSerum MUC5AC in patients with PC (210.1 [100.5–423.8] ng/mL) presented higher levels than those in controls. The combined biomarker panel (MUC5AC and CA19-9) presented better performance and improved specificity to differentiate PC from controls (AUC 0.894; 95% CI (0.844–0.943), sensitivity 0.738, specificity 0.886) than CA19-9 (p = 0.043) or MUC5AC alone (p = 0.010); however, the latter two had no difference (p = 0.824).ConclusionsSerum MUC5AC is a potential biomarker for PC. The combination with CA19-9 presents improved specificity and better performance.
Highlights
Pancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis [1]
Kaur et al [11] evaluated the utility of Mucin 5AC (MUC5AC) in PC detection at the levels of tissue and circulating, in a multi-central
The Areas under the curve (AUC) for PC was 0.836, with a sensitivity of 0.820 and specificity of 0.618 (Table 2 and Fig. 2a)
Summary
Pancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis [1]. The past decades witness the constant increase of the incidence, and it is going to become the second most fatal cancer in 2030 [2].In the clinic, there are still no reliable early detection tools and limited options of therapy, which lead to a dismal prognosis [1, 3]. Pancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis [1]. Pancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis that lacks specific diagnostic markers. Mucin 5AC (MUC5AC) is a member of the mucin family, a heterogeneous group of high molecular weight, heavily glycosylated proteins that could be either membrane-bound or secreted. This multicentral study is to evaluate the performance of serum MUC5AC in combination with carbohydrate antigen 19-9 (CA19-9) for the diagnosis of PC in Asian
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
